Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2011250038) titled 'TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy' on Oct. 3.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Alnylam Pharmaceuticals, Inc
Condition:
Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
C567782
Intervention:
Investigational Drug
Clinical Trial Component Code: ALN-TTRSC04
Non-Proprietary Name: Nucresiran (INN)
Pharmacological Classification Code: 219 Other Cardiovascular
Drugs Dosage and Administration: 300 mg subcu...